The VeriDose® DPYD Panel targets a set of 9 DPYD variants associated with an increased risk of severe toxicity, including the 5 variants recommended by the European Medical Agency and the 4 variants of primary relevance as noted by the CPIC. The single well panel can be run either alone or side-by-side with other genotyping research panels.